Patents by Inventor Heidrun Degen

Heidrun Degen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11072643
    Abstract: The present invention relates to a fusion protein selectively binding collagen and having ectonucleotidase activity. The fusion protein comprises an amino acid sequence of the extracellular domain of glycoprotein VI fused via a first linker sequence to the N-terminus of an amino acid sequence of an Fc region, whereby the C-terminus of the Fc region is linked via a second linker sequence to an amino acid sequence of the extracellular domain of a CD39 protein. The fusion protein is useful in the treatment or prevention of cardiovascular disease or diabetes, such as in the treatment of acute atherothrombotic events with a favorable risk-benefit ratio.
    Type: Grant
    Filed: July 3, 2018
    Date of Patent: July 27, 2021
    Assignee: ADVANCECOR GMBH
    Inventors: Heidrun Degen, Silvia Goebel, Kristin Adler, Martin Ungerer
  • Publication number: 20200216513
    Abstract: The present invention relates to a fusion protein selectively binding collagen and having ectonucleotidase activity. The fusion protein comprises an amino acid sequence of the extracellular domain of glycoprotein VI fused via a first linker sequence to the N-terminus of an amino acid sequence of an Fc region, whereby the C-terminus of the Fc region is linked via a second linker sequence to an amino acid sequence of the extracellular domain of a CD39 protein. The fusion protein is useful in the treatment or prevention of cardiovascular disease or diabetes, such as in the treatment of acute atherothrombotic events with a favorable risk-benefit ratio.
    Type: Application
    Filed: July 3, 2018
    Publication date: July 9, 2020
    Inventors: Heidrun DEGEN, Silvia Goebel, Kristin ADLER, Martin UNGERER
  • Publication number: 20130130315
    Abstract: An isolated nucleic acid molecule selected from the group consisting of: vi. a nucleic acid molecule comprising a nucleotide sequence which is at least 85% identical to the nucleotide sequence of SEQ ID NO:1 or a complement thereof; vii. a nucleic acid molecule comprising a fragment of at least 1500 consecutive nucleotides of the nucleotide sequence of SEQ ID NO:1, or a complement thereof; viii. a nucleic acid molecule which encodes a polypeptide comprising an amino acid sequence at least 85% identical to SEQ ID NO:2; ix. a nucleic acid molecule which encodes a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO:2, wherein the fragment comprises at least 500 contiguous amino acids of SEQ ID NO: 2; and x.
    Type: Application
    Filed: April 6, 2011
    Publication date: May 23, 2013
    Applicant: ADVANCECOR GMBH
    Inventors: Meinrad Gawaz, Tanja Schönberger, Heidrun Degen, Götz Münch, Hans-Peter Holthoff, Andreas Bültmann, Hans-Jörg Bühring, Christoph Leder